Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 18/20 | 0.55 |
| ▸ | NPY1R | P25929 | 11/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.55 |
| ▸ | NPY2R | P49146 | 7/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29422322 | 0.99 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL31232438 | 0.99 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30544772 | 0.99 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL31621730 | 0.97 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL17880650 | 0.97 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30493150 | 0.97 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL29405969 | 0.97 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30272480 | 0.97 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30527822 | 0.97 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RERAP2 | |
| SCHEMBL30531629 | 0.96 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2023532490-A | — | リー、フェンチァオ | 2023-07-28 | — | — | JP | disclosed |
| US-20230210939-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | VITEK, MICHAEL PETER | 2023-07-06 | — | — | US | disclosed |
| CN-116194463-A | Cyclic peptide compounds and methods of use | 李丰桥 | 2023-05-30 | — | — | CN | disclosed |
| CN-116194463-A | Cyclic peptide compounds and methods of use | 李丰桥 | 2023-05-30 | — | — | CN | disclosed |
| EP-4172176-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | Li, Fengqiao (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-4172176-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | Li, Fengqiao (US) | 2023-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210939-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | VIP, NPPA, IAPP | NPY4R 118/4885NPY1R 52/4885NPY5R 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.